Clinical trials: Lung Cancer Recurrent
Lung Cancer
Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy
RATIONALE: Drugs used in chemotherapy, such as carboplatin and ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00998101
- Testing
- cetuximab, carboplatin, ixabepilone
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
This phase II trial studies how well atezolizumab and cobimetinib work in treating patients with non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (metastatic), has…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT03600701
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 18 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasm Metastasis
Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors
The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be adequately tolerated with minimal side effects.
- Trial name
- NCT02313012
- Testing
- CC-90003
- Where
- 5 sites in United States, Australia
- Volunteers
- 19 people
- Sponsor
- Celgene
Lymphoma, Metastatic Malignant Solid Neoplasm
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
This phase I trial studies the best dose and side effects of trigriluzole in combination with nivolumab and pembrolizumab in treating patients with solid malignancies or lymphoma that has spread to other places in the body or…
- Conditions
- Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer
- Trial name
- NCT03229278
- Testing
- Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Rutgers, The State University of New Jersey
Non-Small Cell Lung Cancer, Adjuvant Therapy
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
This multicenter, randomized, open-label, phase II trial is designed to evaluate the efficacy and safety of adjuvant sintilimab in patients with completely resected non-small cell lung cancer who remain at high risk of recurrence…
- Conditions
- Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- RICA (NCT07748325)
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sichuan University
Lung Cancer
PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544674
- Testing
- PR104, F-18-fluoromisonidazole
- Where
- 18 sites in United States
- Volunteers
- 5 people
- Sponsor
- Proacta, Incorporated
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Metastatic Cancer
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Romidepsin and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT01302808
- Testing
- Erlotinib plus Romidepsin (8 mg/m^2), Erlotinib plus Romidepsin (10 mg/m^2), Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Texas Southwestern Medical Center
Cancer
Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation
RATIONALE: Antivirals such as ribavirin are used to treat infections caused by viruses. It is not yet known if ribavirin is more effective with or without monoclonal antibody therapy in treating patients who develop RSV pneumonia…
- Trial name
- NCT00014391
- Testing
- palivizumab, ribavirin
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Squamous Cell Lung Cancer
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug called a BET inhibitor.
- Trial name
- NCT05607108
- Testing
- ZEN003694
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer
TG4010 and Nivolumab in Patients With Lung Cancer
This phase II trial studies how well TG4010 and nivolumab work in previously treated patients with non-small cell lung cancer. Vaccines that are made from a gene-modified virus, such as TG4010, may help the body build an…
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer
- Trial name
- NCT02823990
- Testing
- TG4010, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Megan Daly, MD
Colorectal Cancer, Metastatic Cancer
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- ERBIFORT (NCT00557102)
- Testing
- cetuximab, filgrastim, fluorouracil
- Where
- France
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute, France
Ultracentral Pulmonary Tumors, Lung Cancer (T1 N0 M0 and T2 N0 M0)
Multicentre Phase II Trial Evaluating Stereotactic Body Radiotherapy on Ultra-central Lung Tumors on MR-Linac
Phase II multicenter trial evaluating the safety, tolerability, and feasibility of MRI-guided stereotactic radiotherapy using MRI-LINAC in patients with ultracentral lung tumors or lymphadenopathy in the context of controlled…
- Conditions
- Ultracentral Pulmonary Tumors, Lung Cancer (T1 N0 M0 and T2 N0 M0), Mediastinal Lymph Node Recurrence From All Types of Primary Cancer, Pulmonary Node Recurrence From All Types of Primary Cancer
- Trial name
- LIN-LUNG-2504 (NCT07733219)
- Testing
- MRI-LINAC radiotherapy
- Volunteers
- 59 people
- Sponsor
- Centre Oscar Lambret
Mesothelioma, Mesothelioma, Malignant
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit…
- Conditions
- Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural
- Trial name
- NCT03907852
- Testing
- gavo-cel, fludarabine, cyclophosphamide
- Where
- 11 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- TCR2 Therapeutics
Lung Cancer
Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer
RATIONALE: Anticoagulants, such as lepirudin, may help prevent blood clots from forming in patients who have received chemotherapy for small cell lung cancer.
- Trial name
- NCT00003726
- Testing
- lepirudin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Bladder Cancer, Breast Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
RATIONALE: The LMB-9 immunotoxin may be able to locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced solid tumors.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00019435
- Testing
- LMB-9 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III
Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer
This trial will examine if the monitoring of daily step counts during a course of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer will enable clinicians to deliver improved supportive care and reduce…
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Recurrent Non Small Cell Lung Cancer
- Trial name
- NCT04878952
- Testing
- Garmin Vivofit Activity Tracker
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- NRG Oncology
Small Cell Lung Cancer
Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC
The purpose of this study is to evaluate the maximum tolerated dose, the activity and the safety profile of the combination of vorinostat and topotecan in patients with recurrent small cell lung cancer
- Trial name
- NCT00697476
- Testing
- topotecan, vorinostat
- Where
- Italy
- Volunteers
- 2 people
- Sponsor
- Armando Santoro, MD
Lung Cancer
S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003587
- Testing
- carboplatin, cisplatin, docetaxel
- Where
- 84 sites in United States
- Volunteers
- 204 people
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.